As a result of the discussion of the contents of the file on 21.01.2021, the Competition Board decided that Novartis and Roche violated Article 4 of Act No. 4054 on the Protection of Competition by engaging in concerted practices in order to popularize the use of the drug Lucentis, which is the more expensive of the two drugs used in various eye diseases, in particular in the treatment of the age-related macular degeneration (AMD), namely Altuzan (Avastin), owned by Roche, and the Novartis-owned Lucentis; thus the said undertakings shall be imposed administrative fines.
Click here for the text of the decision dated 21.01.2021 and numbered 21-04/52-21”